Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2366 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Venugopal P Marasanapalle und 9 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Healthcare Private Limited, Hyderabad, India. Hauptthemen laut MEDLINE: Dextromethorphan, Desipramine, Cytochrome P-450 CYP2D6, Genotype. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
This study investigated the differences in the pharmacokinetics (PK) of dextromethorphan and desipramine in healthy African volunteers to understand the effect of allelic variants of the human cytochrome P450 2D6 (CYP2D6) enzyme, namely the diplotypes of CYP2D6*1 / *2 ( *1*1 , *1*2 , *2*2 ) and the genotypes of CYP2D6*17*17 and CYP2D6*29*29 . Overall, 28 adults were included and split into 3 cohorts after genotype screening: CYP2D6*1 / *2 (n = 12), CYP2D6*17*17 (n = 12), and CYP2D6*29*29 (n = 4). Each subject received a single oral dose of dextromethorphan 30 mg syrup on day 1 and desipramine 50 mg tablet on day 8. The PK parameters of area under the plasma concentration‐time curve from time of dosing to time of last quantifiable concentration (AUC last ), and extrapolated to infinity (AUC inf ), and the maximum plasma concentration (C max ) were determined. For both dextromethorphan and desipramine, AUC inf and C max were higher in subjects of the CYP2D6*29*29 and CYP2D6*17*17 cohorts, as compared with subjects in the CYP2D6*1 / *2 diplotype cohort and with normal metabolizers from the literature. All PK parameters, including AUC inf , C max , and the elimination half‐life, followed a similar trend: CYP2D6*17*17 > CYP2D6*29*29 > CYP2D6*1 / *2 . The plasma and urinary drug/metabolite exposure ratios of both drugs were higher in subjects of the CYP2D6*17*17 and CYP2D6*29*29 cohorts, when compared with subjects in the CYP2D6*1 / *2 diplotype cohort. All adverse events were mild, except in 1 subject with CYP2D6*17*17 who had moderately severe headache with desipramine. These results indicate that subjects with CYP2D6*17*17 and CYP2D6*29*29 genotypes were 5‐10 times slower metabolizers than those with CYP2D6*1 / *2 diplotypes. These findings suggest that dose optimization may be required when administering CYP2D6 substrate drugs in African patients. Larger studies can further validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novartis Healthcare Private Limited, Hyderabad, India.
- African Institute of Biomedical Science & Technology (AiBST), Harare, Zimbabwe.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
ORCID-Profile: Nyasha Nicole Kapungu, Comfort Kanji
Zitieren
APA
Marasanapalle, V. P., Masimirembwa, C., Sivasubramanian, R., Sayyed, S., Weinzierl-Hinum, A., Mehta, D., Kapungu, N. N., Kanji, C., Thelingwani, R., & Zack, J. (2024). Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2366
Vancouver
Marasanapalle VP, Masimirembwa C, Sivasubramanian R, Sayyed S, Weinzierl-Hinum A, Mehta D, et al. Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2366
BibTeX
@article{Marasanapalle2024,
author = {Marasanapalle, Venugopal P and Masimirembwa, Collen and Sivasubramanian, Rama and Sayyed, Sarfaraz and Weinzierl-Hinum, Armin and Mehta, Dheeraj and Kapungu, Nyasha Nicole and Kanji, Comfort and Thelingwani, Roslyn and Zack, Julia},
title = {Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2366}
}
EUVIMED